Amantadine resistance among highly pathogenic avian influenza viruses (H5N1) isolated from India

Microbial Pathogenesis

Volumn 91, Issue , 2016, Pages 35-40

  Jacob, Aron ^a   Sood, Richa ^a   Chanu, Kh Victoria ^a   Bhatia, Sandeep ^a   Khandia, Rekha ^a   Pateriya, A K ^a   Nagarajan, S ^a   Dimri, U ^b   Kulkarni, D D ^a  

^a ICAR National Institute of High Security Animal Diseases   (India)

^b INDIAN VETERINARY RESEARCH INSTITUTE   (India)

Author keywords

Amantadine; Antiviral resistance; Avian influenza; Matrix

Indexed keywords

ALANINE; AMANTADINE; ASPARAGINE; RIBONUCLEOPROTEIN; SERINE; VALINE; ANTIVIRUS AGENT;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EC50; HOST CELL; INDIA; INFLUENZA A VIRUS (H5N1); LIFE CYCLE STAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; VIRION; VIRUS ISOLATION; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; BIRD; BIRD DISEASE; CLASSIFICATION; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; VIROLOGY;

AMANTADINE; ANIMALS; ANTIVIRAL AGENTS; BIRD DISEASES; BIRDS; DRUG RESISTANCE, VIRAL; INDIA; INFLUENZA A VIRUS, H5N1 SUBTYPE;

EID: 84959355281     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2015.11.008     Document Type: Article

References (32)

1. Capua I., Alexander D.J. The challenge of avian influenza to the veterinary community. Avian Pathol. 2006, 35:189-205.
2. Continued evolution of highly pathogenic avian influenza A (H5N1): updated nomenclature. Influenza Other Respir. Viruses 2012, 6:1-5. WHO/OIE/FAO H5N1 Evolution Working Group, PubMed: 22035148.
3. World Health Organization. Cumulative number of confirmed human cases for avian influenza A (H5N1) reported to WHO. (accessed 30.10.15) . http://www.who.int/influenza/human_animal_interface/H5N1_cumulative_table_archives/en/.
4. Holsinger L.J., Lamb R.A. Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds. Virology 1991, 183:32-43.
5. Holsinger L.J., Nichani D., Pinto L.H., Lamb R.A. Influenza A virus M2 ion channel protein: a structure-function analysis. J. Virol. 1994, 68:1551-1563.
6. Chen B.J., Leser G.P., Jackson D., Lamb R.A. The influenza virus M2 protein cytoplasmic tail interacts with the M1 protein and influences virus assembly at the site of virus budding. J. Virol. 2008, 82:10059-10070.
7. Bauer C.M., Pinto L.H., Cross T.A., Lamb R.A. The influenza virus M2 ion channel protein: probing the structure of the transmembrane domain in intact cells by using engineered disulfide cross-linking. Virology 1999, 254:196-209.
8. Pinto L.H., Holsinger L.J., Lamb R.A. Influenza virus M2 protein has ion channel activity. Cell 1992, 69:517-528.
9. Sugrue R.J., Tan B.H., Yeo D.S., Sutejo R. Antiviral drugs for the control of pandemic influenza virus. Ann. Acad. Med. Singap. 2008, 37:518-524.
10. Lamb R.A., Kurg R.M. Orthomyxoviridae: the virus and their replication. Field Virology 2001, 1487-1532. Lippincott William and Wikins, Philadelphia, USA. fourth ed. D.M. Knipe, P.M. Howley (Eds.).
11. Deyde V.M., Okomo-Adhiambo M., Sheu T.G., Wallis T.R., Fry A., Dharan N., et al. Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. Antivir. Res. 2009, 81:16-24.
12. Belshe R.B., Smith M.H., Hall C.B., Betts R., Hay A.J. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J. Virol. 1988, 62:1508-1512.
13. Bright R.A., Medina M.J., Xu X., Perez-Oronoz G., Wallis T.R., Davis X.M., et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005, 366:1175-1181.
14. Cheng P.K.C., Leung T.W.C., Ho E.C.M., Leung P.C.K., Ng A.Y.Y., Lai M.Y.Y., et al. Oseltamivir and amantadine- resistant influenza viruses A (H1N1). Emerg. Infect. Dis. 2009, 15:966-968.
15. Cheung C.L., Rayner J.M., Smith G.J., Wang P., Naipospos T.S., Zhang J., et al. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J. Infect. Dis. 2006, 193:1626-1629.
16. Deyde V.M., Xu X., Bright R.A., Shaw M., Smith C.B., Zhang Y., et al. Surveillance of resistance to adamantanes among influenza A (H3N2) and A (H1N1) viruses isolated worldwide. J. Infect. Dis. 2007, 196:249-257.
17. Monne I., Fusaro A., Al-Blowi M.H., Ismail M.M., Khan O.A., Dauphin G., et al. Co-circulation of two sublineages of HPAI H5N1 virus in the Kingdom of Saudi Arabia with unique molecular signatures suggesting separate introductions into the commercial poultry and falconry sectors. J. Gen. Virol. 2008, 89:2691-2697. PubMed: 18931064.
18. Tosh C., Murugkar H.V., Nagarajan S., Tripathy S., Katare M., Jain R., et al. Emergence of amantadine resistant avian influenza H5N1 virus in India. Virus Genes 2011, 42:10-15.
19. Hayden F., Klimov A., Tashiro M. Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses. Antivir. Ther. 2005, 10:873-877.
20. Le M.T.Q., Wertheim H.F.L., Nguyen H.D., Taylor W., Hoang P.V.M. Influenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profile replaced clade 1 virus in humans in Northern Vietnam. PLoS One 2008, 3:e3339. PubMed: 18836532.
21. Tosh C., Nagarajan S., Murugkar H.V., Kumar M., Pandey M., Jolhe D.K., et al. Emergence of Val27Ala mutation in M2 protein associated with amantadine resistance in highly pathogenic avian influenza H5N1 viruses in India. Acta Virol. 2014, 58:389-392.
22. Virus isolation and passage in embryonated chicken eggs. WHO Global Influenza Surveillance Network Manual for the Laboratory Diagnosis and Virological Surveillance of Influenza 2011, 39. WHO Press, World Health Organization, Geneva.
23. Smee D.F., Morrison A.C., Barnard D.L., Sidewell R.W. Comparison of colorimetric, fluorometric and visual methods for determining anti-influenza (H1N1 and H3N2) virus activities and toxicities of compounds. J. Virol. Methods 2002, 106:71-79.
24. Sanger F., Nicklen S., Coulson A.R. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. U. S. A. 1977, 74:5463-5467.
25. Hoffmann E., Stech J., Guan Y., Webster R.G., Perez D.R. Universal primer set for the full-length amplification of all influenza A viruses. Arch. Virol. 2001, 146:2275-2289.
26. Nguyen J.T., Hoopes J.D., Le M.H., Smee D.F., Patick A.K., Faix D.J., et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 2010, 5:9332.
27. Jing X., Ma C., Ohigashi Y., Oliveira F.A., Jardetzky T.S., Pinto L.H., et al. Functional studies indicate amantadine binds to the pore of the influenza A virus M2 proton-selective ion channel. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:10967-10972.
28. Garcia J., Sovero M., Torres A.L., Gomez J., Douce R., Barrantes M., et al. Antiviral resistance in influenza viruses circulating in Central and South America based on the detection of established genetic markers. Influenza Resp. Viruses 2009, 3:69-74.
29. Hay A.J., Wolstenholme A.J., Skehel J.J., Smith M.H. The molecular basis of the specific anti-influenza action of amantadine. Embo J. 1985, 4:3021-3024.
30. Astrahan P., Kass I., Cooper M.A., Arkin I.T. A novel method of resistance for influenza against a channel-blocking antiviral drug. Proteins 2004, 55:251-257.
31. Krumbholz A., Schmidtke M., Bergmann S., Motzke S., Bauer K., Stech J., et al. High prevalence of amantadine resistance among circulating European porcine influenza A viruses. J. Gen. Virol. 2009, 90:900-908.
32. Peiris J.S., de Jong M.D., Guan Y. Avian influenza virus (H5N1): a threat to human health. Clin. Microbiol. Rev. 2007, 20:243-267.